To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease.
作者信息
Shin Dong Ho
机构信息
Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
出版信息
Kidney Res Clin Pract. 2019 Sep 30;38(3):257-259. doi: 10.23876/j.krcp.19.074.
Abstract
摘要
相似文献
1
To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease.慢性肾脏病中无症状高尿酸血症的治疗与否
Kidney Res Clin Pract. 2019 Sep 30;38(3):257-259. doi: 10.23876/j.krcp.19.074.
2
Asymptomatic hyperuricemia: is it time to intervene?无症状高尿酸血症：是否到了需要干预的时候？
Clin Rheumatol. 2017 Dec;36(12):2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct 4.
3
Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.降尿酸药物治疗 3-4 期慢性肾脏病无症状高尿酸血症：肾功能的争议作用。
PLoS One. 2019 Jun 17;14(6):e0218510. doi: 10.1371/journal.pone.0218510. eCollection 2019.
4
Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.无症状高尿酸血症的治疗与血管疾病的预防：一种决策分析方法
J Rheumatol. 2014 Apr;41(4):739-48. doi: 10.3899/jrheum.121231. Epub 2014 Mar 1.
5
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound.无症状高尿酸血症中的降尿酸药物：尿沉渣分析和肌肉骨骼超声的作用
Kidney Blood Press Res. 2018;43(2):606-615. doi: 10.1159/000489145. Epub 2018 Apr 19.
6
The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.轻度高尿酸血症对尿转化生长因子β及慢性肾脏病进展的影响。
Am J Nephrol. 2007;27(5):435-40. doi: 10.1159/000105142. Epub 2007 Jul 4.
7
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.非布司他治疗 3 期 CKD 合并无症状高尿酸血症患者：一项随机试验。
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
8
Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study.别嘌醇治疗可改善2型糖尿病合并无症状高尿酸血症患者的肾功能：一项为期3年的随机平行对照研究。
Clin Endocrinol (Oxf). 2015 Oct;83(4):475-82. doi: 10.1111/cen.12673. Epub 2014 Dec 29.
9
[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].[尿酸作为心血管疾病和肾脏疾病的潜在危险因素]
Acta Med Croatica. 2016 Dec;70(4-5):233-9.
10
Hyperuricemia and associated diseases.高尿酸血症及相关疾病。
Rheum Dis Clin North Am. 2006 May;32(2):275-93, v-vi. doi: 10.1016/j.rdc.2006.02.005.
引用本文的文献
1
Deciphering the role of cell signaling pathways in gout pathogenesis and the therapeutic potential of phytoconstituents in their modulation.解析细胞信号通路在痛风发病机制中的作用以及植物成分在调节这些通路方面的治疗潜力。
Inflammopharmacology. 2025 Apr 18. doi: 10.1007/s10787-025-01741-x.
2
Hyperuricemia, a Non-Independent Component of Metabolic Syndrome, Only Predicts Renal Outcome in Chronic Kidney Disease Patients without Metabolic Syndrome or Diabetes.高尿酸血症是代谢综合征的非独立组成部分，仅能预测无代谢综合征或糖尿病的慢性肾脏病患者的肾脏结局。
Biomedicines. 2022 Jul 16;10(7):1719. doi: 10.3390/biomedicines10071719.
3
Late presentation of severe gouty tophi affecting both hands.晚期严重痛风石累及双手。
BMJ Case Rep. 2022 Jan 17;15(1):e246818. doi: 10.1136/bcr-2021-246818.
4
Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease.血清尿酸与慢性肾脏病患者左心室肥厚/左心室舒张功能障碍的关系。
PLoS One. 2021 May 6;16(5):e0251333. doi: 10.1371/journal.pone.0251333. eCollection 2021.
5
Renal effects of uric acid: hyperuricemia and hypouricemia.尿酸对肾脏的影响：高尿酸血症与低尿酸血症。
Korean J Intern Med. 2020 Nov;35(6):1291-1304. doi: 10.3904/kjim.2020.410. Epub 2020 Sep 9.
本文引用的文献
1
Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey.医生对慢性肾脏病患者无症状高尿酸血症的认知：一项问卷调查
Kidney Res Clin Pract. 2019 Sep 30;38(3):373-381. doi: 10.23876/j.krcp.19.007.
2
How should we manage asymptomatic hyperuricemia?无症状高尿酸血症应该如何治疗？
Joint Bone Spine. 2019 Jul;86(4):437-443. doi: 10.1016/j.jbspin.2018.10.004. Epub 2018 Oct 11.
3
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.中重度慢性肾脏病的降尿酸治疗
Perm J. 2018;22:17-142. doi: 10.7812/TPP/17-142.
4
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.非布司他治疗 3 期 CKD 合并无症状高尿酸血症患者：一项随机试验。
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
5
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
6
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.一项评估非布司他对高尿酸血症患者预防脑、心血管和肾脏事件效果的研究的原理、设计及基线特征
J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20.
7
Essence of the revised guideline for the management of hyperuricemia and gout.高尿酸血症和痛风管理修订指南的要点
Japan Med Assoc J. 2012 Jul;55(4):324-9.
8
Renal transport of uric acid: evolving concepts and uncertainties.尿酸的肾脏转运：不断发展的概念和不确定性。
Adv Chronic Kidney Dis. 2012 Nov;19(6):358-71. doi: 10.1053/j.ackd.2012.07.009.
9
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.2012年美国风湿病学会痛风管理指南。第1部分：高尿酸血症的系统性非药物和药物治疗方法。
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772.
10
Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey.日本肾病学家对慢性肾脏病患者无症状高尿酸血症的管理：问卷调查。
Nephrology (Carlton). 2011 Jul;16(5):518-21. doi: 10.1111/j.1440-1797.2011.01446.x.
Zotero 插件